Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The brokerage presently has a $9.75 price objective on the stock. Zacks Investment Research‘s target price points to a potential upside of 18.33% from the company’s current price.
According to Zacks, “Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables. Endo has centralized and streamlined its supply chain, quality and compliance organization in order to create a more cohesive and efficient structure. The company plans to close its Huntsville, Alabama manufacturing and distribution facilities over the next 12 to 18 months due to declining volumes of commoditized products that affected the Huntsville location. The company expects to transfer majority of the products to other sites while discontinuing approximately 15 products starting in the fourth quarter of 2017 and continuing through 2018. This restructuring is intended to better match manufacturing capacity to projected future demand. However, headwinds in the form of declining generics base business and the legacy branded pain franchise remain. Shares have significantly underperformed the industry so far in 2017.”
Several other research firms have also issued reports on ENDP. Goldman Sachs Group, Inc. (The) initiated coverage on Endo International PLC in a report on Thursday, September 28th. They issued a “sell” rating and a $7.00 target price for the company. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $9.00 target price on shares of Endo International PLC in a report on Sunday, September 17th. Mizuho reaffirmed a “buy” rating and issued a $14.00 target price (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a report on Tuesday, August 8th. Finally, Deutsche Bank AG reduced their target price on Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, July 7th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $12.64.
Endo International PLC (NASDAQ ENDP) traded down 1.5862% during mid-day trading on Wednesday, hitting $8.1093. The stock had a trading volume of 2,558,515 shares. The firm’s 50-day moving average price is $8.70 and its 200-day moving average price is $10.57. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $21.87. The stock’s market cap is $1.81 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.86 earnings per share. On average, equities analysts expect that Endo International PLC will post $3.52 earnings per share for the current year.
In related news, CEO Paul Campanelli bought 6,500 shares of the company’s stock in a transaction on Monday, August 14th. The shares were purchased at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the transaction, the chief executive officer now directly owns 213,620 shares in the company, valued at approximately $1,647,010.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 36,000 shares of company stock worth $279,460. Company insiders own 0.50% of the company’s stock.
Large investors have recently bought and sold shares of the business. Gamco Investors INC. ET AL lifted its position in shares of Endo International PLC by 5.6% during the second quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company’s stock worth $700,000 after acquiring an additional 3,300 shares in the last quarter. James Investment Research Inc. purchased a new stake in shares of Endo International PLC during the second quarter worth $113,000. Russell Investments Group Ltd. lifted its position in shares of Endo International PLC by 20.9% during the second quarter. Russell Investments Group Ltd. now owns 325,860 shares of the company’s stock worth $3,640,000 after acquiring an additional 56,407 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Endo International PLC during the second quarter worth $2,793,000. Finally, Columbia Partners L L C Investment Management purchased a new stake in shares of Endo International PLC during the second quarter worth $1,257,000. Hedge funds and other institutional investors own 90.71% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.